Kisspeptin-10 is the ten-amino-acid end fragment of the hormone kisspeptin, sold online as a research vial, most often labelled 10 mg. It has no FDA approval, and FDA found no approved product containing it in any country. FDA has listed it as a compounding safety risk (503A Category 2) since 29 September 2023. FDA's compounding advisers voted 0 to 11 against adding it to the 503A bulks list on 29 October 2024. On the public lab record the vials test well. Across 24 results, none was graded a fail, median purity was 99.90% and the median vial held 110.9% of its label. Two of 21 fill results came in under label, the lowest at 93.2%. The record is small, and every result is one a vendor or buyer chose to publish. We tested none of these vials ourselves.
Kisspeptin-10 tests well on the public record, and the record is small: 24 results, 0 graded a fail, median purity 99.90%, median fill 110.9% of label. None of 21 fill results came in under 90%. These are results that vendors and buyers chose to publish, not a random sample of what is sold. FDA has listed kisspeptin-10 as a compounding safety risk since 2023. Its compounding advisers voted 0 to 11 against it in October 2024.
Kisspeptin-10 at a glance.
| What it is | A synthetic ten-amino-acid fragment of kisspeptin (metastin 45-54) |
| Most common label | 10 mg (20 of 24 results); 5 mg on 3 |
| Lab results we mirror | 24, on 27 certificates, from 5 sources |
| Client names | 21 on the 24 results; 24 counting re-issued copies |
| Test dates | 30 Jun 2025 to 2 Jul 2026 |
| Median fill | 110.9% of label (21 results) |
| Lowest / highest fill | 93.2% / 123.2% |
| Under label / under 90% | 2 of 21 / 0 |
| Median purity | 99.90% (23 results), lowest 99.00% |
| Graded fail / identity failed | 0 / 0 |
| Carry an endotoxin result | 15 of 24 (all Kovera) |
| Carry a sterility screen | 10 of 24 (all Kovera) |
| US approval | None; FDA found no approved product in any country |
| 503A compounding | Category 2 since 29 Sep 2023; committee voted 0 to 11 against, 29 Oct 2024 |
| HHS policy, 28 Oct 2026 | Not among the six peptides covered |
Sources for each row are in the sections below.
What is in the vial.
FDA's briefing document for the October 2024 meeting describes kisspeptin-10 as a synthetic, non-glycosylated peptide of ten amino acids with the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, molecular weight 1302 g/mol. The KISS1 gene encodes a 145-amino-acid protein that is cut into kisspeptin-54, -14, -13 and -10. All four share the same ten-residue end, which is kisspeptin-10. It binds the receptor GPR54, also called KISS1R, which is concentrated in the hypothalamus. FDA's review cites a plasma half-life of about four minutes after intravenous infusion, 3.8 minutes in the men studied (FDA briefing, kisspeptin-10).
FDA found no kisspeptin-10 monograph in the US, European or Japanese pharmacopoeias and no approved product containing it in any country. The same briefing notes that "other websites market kisspeptin-10" as a 10 mg product for research use, the format every result on this page covers.
Sellers use more than one name. Kovera certificates read "Kisspeptin-10" or "Kisspeptin". Ion Peptide sells it as KSPTN, one of the code names in our code-name catalogs report.
We make no claim about what kisspeptin-10 does in people.
The US regulatory record.
| Date | Event | Source |
|---|---|---|
| 29 Sep 2023 | FDA places kisspeptin-10 in 503A Category 2: bulk substances that may present significant safety risks in compounding | FDA Category 2 page |
| 5 Jul 2024 | FDA's evaluation, nominated by Wells Pharmacy Network for secondary hypogonadism in men, concludes the criteria weigh against listing | FDA briefing document |
| 29 Oct 2024 | Pharmacy Compounding Advisory Committee votes against adding kisspeptin-10 to the 503A bulks list: 0 yes, 11 no, 0 abstain | Final summary minutes, 29 Oct 2024 |
| 22 Apr 2026 | FDA's Category 2 page, content current as of this date, still lists kisspeptin-10 under 503A (read 19 Nov 2026) | FDA Category 2 page |
| 28 Oct 2026 | HHS files its 503A peptide enforcement-discretion policy; kisspeptin-10 is not among the six | Federal Register doc 2026-22192 |
The vote. The minutes record a unanimous no "due to the lack of convincing safety and efficacy data". FDA's evaluation found the substance not well characterized: it found no public data on likely impurities, and the nominator's certificate gave only total-impurity limits, not the individual impurities. It raised a concern about immunogenicity for the injected routes nominated, under the skin and into muscle. It found no human study of the intramuscular route and one subcutaneous study, in healthy women, that did not report safety outcomes.
Category 2. FDA's risk note for kisspeptin-10 says compounded drugs containing it may pose a risk of immunogenicity for certain routes, and that FDA has no, or only limited, safety information for the proposed routes. Kisspeptin-10 was not among the twelve substances FDA said in April 2026 it would remove from Category 2. Our FDA peptide vote explainer lists those twelve.
The HHS policy. The HHS policy text covers BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. Kisspeptin-10 is not one of them. Our HHS policy explainer covers the conditions.
Kisspeptin-10 is not a controlled substance, and federal law does not make possessing it a crime. Selling it for human use is selling an unapproved drug. The WADA 2026 prohibited list names "kisspeptin and its agonist analogues" under S2.2.1, testosterone-stimulating peptides in males, a class prohibited at all times. Our peptide legality tool keeps the sources together.
What 24 public lab results show.
We pooled kisspeptin results from the certificate sources in our 2,087-result purity study, with the same rule for duplicates: two certificates from one source with the same measured milligrams, purity and test date count as one result. Five sources carried kisspeptin; Particle Peptides had none.
| Source | Results | What it reports | Median fill | Median purity | Test dates | Mirrored |
|---|---|---|---|---|---|---|
| Kovera Labs public verifier | 19 (22 certificates) | Net content, purity, identity; endotoxin and sterility on some | 110.9% (17) | 99.93% (18) | Mar to Jul 2026 | Aug 2026, re-read 10 Nov 2026 |
| Janoshik public tests | 2 | Amount, purity, identity | 102.0%, 123.2% | 99.67%, 99.69% | Jan to Feb 2026 | 30 Jun 2026 snapshot |
| Injectify test reports (Janoshik #97374) | 1 | Amount, purity, identity | 110.9% | 99.67% | Jan 2026 | May 2026 |
| Ascension Peptides COA page (MZ Biolabs) | 1 | Purity, identity | not reported | 99.00% | Jun 2025 | May 2026 |
| Swiss Chems test-results page | 1 | Amount, purity, identity | 99.6% | 99.80% | Mar 2026 | May 2026 |
| All sources | 24 | 110.9% (21) | 99.90% (23) | Jun 2025 to Jul 2026 |
Three of the 27 certificates are copies. One 5 mg Kovera result (KVR-2026-5C3769, 22 March 2026) appears on three certificates under three client names, two of them with an -S suffix. Two more Kovera certificates, KVR-2026-5D72AB and KVR-2026-C9F7C3, print different clients, lots and order numbers but the same results to the third decimal, dated 7 March 2026; under our rule they count once. Swiss Chems publishes one certificate as two pages, the second an LC-MS identity spectrum, which we count once. We left out one Janoshik catalogue entry (#74148) with no readable result, and one Kovera certificate (KVR-2026-42AFE8) reports identity only, so it counts as a result with no fill or purity figure.
Our October purity study counted 25 kisspeptin results, with a slightly different name match. Its median fill, 110.9%, is the same.
Fill: how much is in the vial.
| Fill band | Results | Share of 21 |
|---|---|---|
| Under 90% of label | 0 | 0% |
| 90% to 100% | 2 | 9.5% |
| 100% to 105% | 3 | 14.3% |
| 105% to 110% | 4 | 19.0% |
| 110% to 115% | 6 | 28.6% |
| 115% to 120% | 4 | 19.0% |
| 120% and over | 2 | 9.5% |
The middle half of results sits between 106.1% and 117.8% of label, and 12 of 21 held more than 110%.
The two results under label:
- Mile High Compounds: 9.32 mg in a 10 mg vial, 93.2% (KVR-2026-C5952D, analysed 6 May 2026). Kovera grades net content a pass against "10mg ± 10%".
- Swiss Chems: 9.96 mg in a 10 mg vial, 99.6%, on the certificate the shop publishes (dated 22 March 2026).
The highest is Janoshik #100564, client Cocer Peptides: 12.32 mg in a 10 mg vial, 123.2%, analysed 19 January 2026.
One certificate left out. Kovera certificate KVR-2026-98009F (analysed 22 April 2026) is not in the fill figures. As served on 10 November 2026, Kovera's record gives 31.29 mg net content (batch average 30.62 mg) against a printed "10mg ± 10%" specification, graded a pass. That is about three times the printed label and far above any other 10 mg kisspeptin vial in the pool. We hold no image of the certificate, so we cannot tell from the served record alone whether the label or the measurement is the error. We draw no conclusion about the vial or the client. Counting it would not change the median fill. Its purity, identity, endotoxin and heavy-metal results are in the other figures.
Specification and grade. As served on 10 November 2026, 10 of the 18 Kovera results with a net-content line print a "± 10%" specification, measure more than 10% over it, and grade net content a pass. Two others, KVR-2026-F8A885 and KVR-2026-07D7EC, print "~10mg" instead. Our re-issued certificates report tracks how Kovera specifications have changed.
Purity.
Purity here is the HPLC (high-performance liquid chromatography) figure the certificate prints.
| Purity band | Results | Share of 23 |
|---|---|---|
| 99.5% or higher | 21 | 91.3% |
| 99% to 99.5% | 2 | 8.7% |
| Under 99% | 0 | 0% |
The lowest is Ascension Peptides' own certificate from MZ Biolabs, 99.00% on 30 June 2025, which prints no net content. The other result under 99.5% is a Kovera certificate at 99.47% (KVR-2026-91FCC6), whose client is printed only as an email address. Ascension also has a Kovera result for kisspeptin: 11.36 mg in a 10 mg vial at 99.85% (KVR-2026-0A332D, 9 May 2026).
Fails and identity.
No result in the 24 was graded a fail, and every certificate that reports identity confirmed it. On the three Ion Peptide certificates the confirmed identity reads "KSPTN", the product code. Kovera's register names two of them kisspeptin-10.
Endotoxin and sterility.
| Test | Results carrying it | Outcome |
|---|---|---|
| Endotoxin | 15 of 24 (all Kovera) | All pass against "≤0.5 EU/mL" (endotoxin units per millilitre); 12 give the result as under 0.10 EU/mL |
| Microbial sterility screen | 10 of 24 (all Kovera) | All "No Growth" |
| Heavy metals | 8 of 24 (all Kovera) | All four metals negative; two more Kovera certificates link a separate heavy-metal report |
The 5 non-Kovera results and 4 Kovera ones carry no endotoxin result. Our endotoxin guide explains why a per-millilitre limit depends on how the lab dissolved the sample.
The selection bias in this record.
Every result here is one that a vendor or buyer chose to send to a lab, and one the lab or vendor chose to publish. Kovera and Janoshik publish fails next to passes, but the client still decides which vials reach them, and a vendor can leave a bad certificate off its own page. Zero fails in 24 describes the published record. It is not a failure rate for kisspeptin on the market.
The record is also small and concentrated. 19 of 24 results are Kovera certificates from a four-month window in 2026, and a single result moves any share in the fill table by almost five points. We last re-read our Kovera mirror on 10 November 2026 and Janoshik's on 30 June 2026, so we count no later certificates.
What a buyer can and cannot conclude.
| You can conclude | You cannot conclude |
|---|---|
| Published kisspeptin vials on this record held at least 93% of label | That a vial you buy holds its label |
| HPLC purity was 99% or higher on every result with a figure | That the vial is free of endotoxin or microbes, unless its own certificate shows those tests |
| Identity was confirmed on every certificate that reports it | That a code-named vial is kisspeptin-10, if its certificate names only the code |
| FDA lists kisspeptin-10 as a compounding safety risk | That a pharmacy can lawfully compound it |
Prices.
Our price index holds no kisspeptin listing in its build of 17 November 2026, so we publish no price per mg for it.
How to read a kisspeptin certificate.
- Check the name. The certificate should name kisspeptin or kisspeptin-10. If it prints a product code such as KSPTN, the identity line confirms the code, not the compound by name.
- Read the specification next to the result. A "pass" against "10mg ± 10%" with 12 mg measured means the grade does not follow the printed specification.
- Look for the panels that are not there. Endotoxin and sterility are separate tests. 9 of the 24 results here carry no endotoxin line.
- Verify at the lab and match the lot. Use Kovera's verifier or Janoshik's, and our guides to verifying a peptide COA and verifying a Janoshik COA. A certificate covers one tested sample.
Our methodology page explains how we read and score lab records.
What we read, and what we did not.
We read 27 kisspeptin certificates in our mirrors of Kovera Labs' public verifier (re-read 10 November 2026), Janoshik's public test listing (30 June 2026), Injectify's test reports (May 2026), and the certificate pages of Ascension Peptides and Swiss Chems (May 2026). We read FDA's kisspeptin-10 briefing document for the 29 October 2024 meeting, the final summary minutes of that meeting, FDA's Category 2 page (current as of 22 April 2026) and the Federal Register notice 2026-22192. We did not test any vial, and we hold no image of certificate KVR-2026-98009F. We do not publish the client email addresses printed on three certificates.
Sources.
- FDA, Kisspeptin-10 briefing document, Pharmacy Compounding Advisory Committee meeting of 29 October 2024 (evaluation dated 5 July 2024)
- FDA, Final summary minutes, Pharmacy Compounding Advisory Committee, 29 October 2024 (approved 15 January 2025)
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of 22 April 2026
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register document 2026-22192, filed 28 October 2026
- HHS, Enforcement discretion policy with Appendix A and Appendix B, October 2026
- WADA, 2026 Prohibited List, September 2025
Frequently asked
What is kisspeptin-10?
A synthetic ten-amino-acid peptide, the shared C-terminal end of the kisspeptin isoforms made from the KISS1 gene. FDA's 2024 briefing document gives its sequence as Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe (amidated) and a molecular weight of 1302 g/mol. It is also called metastin 45-54. It binds the kisspeptin receptor, KISS1R (also GPR54).
Are kisspeptin vials underfilled?
Rarely, on the published record. Of 21 results that give a measured amount against a label, none was under 90% and two were under label: 9.32 mg in a 10 mg vial (93.2%, Kovera KVR-2026-C5952D) and 9.96 mg in a 10 mg vial (99.6%, Swiss Chems' own certificate). The median was 110.9% of label and the highest 123.2%.
How pure are kisspeptin vials on the public record?
Across 23 results with a purity figure, median HPLC purity was 99.90%. None was under 99%. The lowest was 99.00%, on Ascension Peptides' own MZ Biolabs certificate from 30 June 2025.
Do kisspeptin certificates test for endotoxin or sterility?
Some do, and all of them are Kovera certificates. 15 of the 24 results carry an endotoxin result and 10 a microbial sterility screen, all passes. The Janoshik, Injectify, Ascension and Swiss Chems certificates in the pool carry neither. Purity and fill say nothing about either.
What is KSPTN?
A product code. Ion Peptide sells kisspeptin under the name KSPTN, and Kovera's register lists two of its three KSPTN certificates as kisspeptin-10. The identity line on all three reads "KSPTN", not the chemical name, so the certificate confirms the code, not the compound by name.
Is kisspeptin-10 FDA approved or compoundable?
Neither. FDA's briefing found no approved kisspeptin-10 product in any country. FDA has listed kisspeptin-10 in 503A Category 2, substances that may present significant safety risks in compounding, since 29 September 2023, and its compounding advisory committee voted 0 to 11 against adding it to the 503A bulks list on 29 October 2024. It is not among the six peptides in the HHS compounding policy filed on 28 October 2026.
Is kisspeptin legal to buy in the US?
It is not a controlled substance, and federal law does not make possessing it a crime. Selling it for human use is selling an unapproved drug, and a "research use only" label does not change that when a shop markets it for people. WADA's 2026 list names kisspeptin and its agonist analogues under S2.2.1, testosterone-stimulating peptides in males, which are prohibited at all times.